Dr. rer. pole. Marco Penske
ORCID: 0009-0003-6708-9257
studied economics at the University of Mainz with a focus on health economics and statistics. After completing his doctorate and working at the Institute for Finance at Johannes Gutenberg University Mainz, he worked for a management consultancy. He has been working at Boehringer Ingelheim in various functions since 2007. He has headed the Market Access and Healthcare Affairs department in Germany since 2011. His areas of responsibility include benefit assessment, payer evidence, pricing and contracting, key account management and healthcare policy. He is also a speaker at conferences and works as a lecturer. As deputy chairman of the German Association for Market Access, he is committed to establishing market access and the exchange between manufacturers and payers.
Articles
- Der ökonomische Impact innovativer Arzneimittel
MVF 04/26
- Comparison of healthcare costs of type 2 diabetics using empagliflozin, DPP-4 inhibitors and GLP-1 agonists (Print)
Issue 06/2022
- "Anyone who tinkers with the AMNOG should know exactly what they are doing"
Issue 05/2022
- “Accompanying data collection in the benefit assessment opens a method discussion”
Issue 03/2019
